Process design phase 1 specifications

In ICP-AES and ICP-MS, sample mineralisation is the Achilles heel. Sample introduction systems for ICP-AES are numerous gas-phase introduction, pneumatic nebulisation (PN), direct-injection nebulisation (DIN), thermal spray, ultrasonic nebulisation (USN), electrothermal vaporisation (ETV) (furnace, cup, filament), hydride generation, electroerosion, laser ablation and direct sample insertion. Atomisation is an essential process in many fields where a dispersion of liquid particles in a gas is required. Pneumatic nebulisation is most commonly used in conjunction with a spray chamber that serves as a droplet separator, allowing droplets with average diameters of typically <10 xm to pass and enter the ICP. Spray chambers, which reduce solvent load and deal with coarse aerosols, should be as small as possible (micro-nebulisation [177]). Direct injection in the plasma torch is feasible [178]. Ultrasonic atomisers are designed to specifically operate from a vibrational energy source [179]. 

When we design commercial polymerization plants we must consider the characteristics of both the monomer and the final product. This allows us to define the optimum configuration to produce a specific polymer. Polymerization reactions can take place in homogeneous solutions or heterogeneous suspensions. For homogeneous processes, the diluted or pure monomer(s) are added directly to one another and the reaction occurs in the media created when mixing the reactants. When the reactants are added directly to one another, the process is referred to as a bulk process. With heterogeneous processes, a phase boundary exists which acts as an interface where the reaction occurs. 

Most survey respondents indicated that they perform reactive hazard evaluation studies during specific life-cycle phases of a process or product. These phases include process development, commercial process design, periodic re-evaluation, and before proposed modifications. The protocol for hazard evaluation of reactive systems varies from company-to-company. At a minimum, all surveyed companies employ qualitative hazard evaluations.58... 

The domain object analysis phase must be very brief in an iterative process. It should be a j-1 day activity after the use case specification is developed. Do not expect the analysis model to be complete, accurate, and unchanging. Many decisions can be, and should be, deferred to the design phase. 

In order to turn these mass-balance equations into design equations, we turn all the rate processes r, f, and RMi into rates per unit volume of the process for the specific phase, namely... 

This process can begin in the design phase - unless there are restrictions on the exchange of information prior to the official closing of the transaction. In cases where such restrictions exist, calling in a clean team (with no employees from the companies concerned) to put the company-specific data into an aggregated, comparable form and then evaluate them can save considerable time. 

Biopharmaceutical clean-rooms typically house process equipment requiring utilities such as pure water, electricity, vacuum, and clean compressed air. The source of these utilities is usually outside the clean room. During the design phase a utility matrix is developed, in conjunction with end users and equipment manufacturers, identifying all equipment and the utilities required. This is the basis for determining the capacity of the utility systems as well as the point-of-use location of specific utilities. 

---